Adrienne Waks
Alliance for Clinical Trials in Oncology · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adrienne Waks as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:02 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06876714 · ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabAlliance for Clinical Trials in Oncology · recruiting · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer · study chair
- Ph2NCT06100874 · A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)Adrienne G. Waks · active not recruiting · Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic · principal investigator
- Ph2NCT04425018 · MARGetuximab Or Trastuzumab (MARGOT)Dana-Farber Cancer Institute · active not recruiting · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer · principal investigator
- Ph2NCT03414658 · The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerAdrienne G. Waks · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT02326974 · T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCADana-Farber Cancer Institute · active not recruiting · HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:02 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.Cancer Discov · 2020372 citationsRCR 13.5
- 256 citationsRCR 11.6
- Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.Cancer Discov · 2021222 citationsRCR 10.9
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Lancet Oncol · 2023152 citationsRCR 12.3
- BP changes in obese hypertensive subjects during rapid weight loss. Comparison of restricted v unchanged salt intake.Arch Intern Med · 198467 citationsRCR 2.7
- 56 citationsRCR 5.3
- Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.J Immunother Cancer · 202240 citationsRCR 2.5
- HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.J Clin Invest · 202436 citationsRCR 4.1
- 17 citationsRCR 0.6
- Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).JCO Oncol Pract · 202516 citationsRCR 3.9